Showing 1 to 12 of 22 results
Greece Warns Against Counterfeit GLP-1 Agonist Drugs
The Greek National Organization for Medicines (EOF) warns against the rising number of illegal GLP-1 agonist drugs sold online, emphasizing severe health risks due to unverified quality and potential harmful substances.
Greece Warns Against Counterfeit GLP-1 Agonist Drugs
The Greek National Organization for Medicines (EOF) warns against the rising number of illegal GLP-1 agonist drugs sold online, emphasizing severe health risks due to unverified quality and potential harmful substances.
Progress
44% Bias Score
NICE Recommends Personalized Treatment for Type 2 Diabetes in UK
NICE recommends personalized type 2 diabetes treatment in England, Wales, and Northern Ireland, prioritizing SGLT-2 inhibitors as first-line treatment for all 4.6 million diagnosed patients, potentially saving 22,000 lives and reducing NHS costs, but addressing unequal access is crucial.
NICE Recommends Personalized Treatment for Type 2 Diabetes in UK
NICE recommends personalized type 2 diabetes treatment in England, Wales, and Northern Ireland, prioritizing SGLT-2 inhibitors as first-line treatment for all 4.6 million diagnosed patients, potentially saving 22,000 lives and reducing NHS costs, but addressing unequal access is crucial.
Progress
48% Bias Score
High Blood Sugar's Hidden Impact: Sexual Dysfunction
Dr. Jamin Brahmbhatt explains how high blood sugar negatively impacts sexual health in both men and women, affecting erectile function, hormone levels, and overall intimacy, often preceding other diabetes symptoms, and emphasizes lifestyle changes and improved blood sugar control for better sexual h...
High Blood Sugar's Hidden Impact: Sexual Dysfunction
Dr. Jamin Brahmbhatt explains how high blood sugar negatively impacts sexual health in both men and women, affecting erectile function, hormone levels, and overall intimacy, often preceding other diabetes symptoms, and emphasizes lifestyle changes and improved blood sugar control for better sexual h...
Progress
44% Bias Score
MHRA Warns Against Weight-Loss Drugs During Pregnancy
The UK MHRA warns against weight-loss drugs like Mounjaro, Ozempic, and Wegovy during pregnancy, breastfeeding, or when trying to conceive due to safety concerns and increased misuse; women should immediately consult their doctor upon discovering pregnancy and use non-oral contraception.
MHRA Warns Against Weight-Loss Drugs During Pregnancy
The UK MHRA warns against weight-loss drugs like Mounjaro, Ozempic, and Wegovy during pregnancy, breastfeeding, or when trying to conceive due to safety concerns and increased misuse; women should immediately consult their doctor upon discovering pregnancy and use non-oral contraception.
Progress
60% Bias Score
Australian Weight Loss Drug Users Report Liver Issues
Dozens of Australians using weight-loss injections Wegovy, Ozempic, and Mounjaro have reported liver problems, including hepatitis, prompting a warning from experts for regular GP check-ups; three cases linked to semaglutide were reported to the TGA.
Australian Weight Loss Drug Users Report Liver Issues
Dozens of Australians using weight-loss injections Wegovy, Ozempic, and Mounjaro have reported liver problems, including hepatitis, prompting a warning from experts for regular GP check-ups; three cases linked to semaglutide were reported to the TGA.
Progress
44% Bias Score
Weight-Loss Injections Show Promise in Extending Lifespans, Preventing Diseases
New weight-loss injections, GLP-1 agonists like Mounjaro and Wegovy, show promise in delaying age-related illnesses and reducing heart attack risk by half, based on a 17,000-patient trial, leading experts to suggest expanded access for up to half of Britons to improve health and longevity.
Weight-Loss Injections Show Promise in Extending Lifespans, Preventing Diseases
New weight-loss injections, GLP-1 agonists like Mounjaro and Wegovy, show promise in delaying age-related illnesses and reducing heart attack risk by half, based on a 17,000-patient trial, leading experts to suggest expanded access for up to half of Britons to improve health and longevity.
Progress
52% Bias Score
Weight-Loss Drugs Halve Heart Failure Hospitalizations and Deaths
A large-scale study reveals that GLP-1 agonists, semaglutide and tirzepatide, significantly reduce hospitalizations and mortality risk by 42% and 58%, respectively, in obese heart failure patients with type 2 diabetes.
Weight-Loss Drugs Halve Heart Failure Hospitalizations and Deaths
A large-scale study reveals that GLP-1 agonists, semaglutide and tirzepatide, significantly reduce hospitalizations and mortality risk by 42% and 58%, respectively, in obese heart failure patients with type 2 diabetes.
Progress
32% Bias Score
GLP-1 Agonists Show Significant Dementia Risk Reduction
A large Irish study of 164,531 participants found that GLP-1 agonists, like Ozempic and Wegovy, reduced dementia risk by 45 percent, potentially offering a preventative measure for both diabetes and dementia, conditions on the rise in the US.
GLP-1 Agonists Show Significant Dementia Risk Reduction
A large Irish study of 164,531 participants found that GLP-1 agonists, like Ozempic and Wegovy, reduced dementia risk by 45 percent, potentially offering a preventative measure for both diabetes and dementia, conditions on the rise in the US.
Progress
44% Bias Score
Weight-Loss Injections Pose Contraceptive Risks: Urgent MHRA Warning
The UK's MHRA issued an urgent warning that weight-loss injections, including Ozempic, Wegovy, and Mounjaro, may reduce contraceptive effectiveness and pose risks to pregnant women and fetuses, prompting advice on birth control and immediate cessation upon pregnancy.
Weight-Loss Injections Pose Contraceptive Risks: Urgent MHRA Warning
The UK's MHRA issued an urgent warning that weight-loss injections, including Ozempic, Wegovy, and Mounjaro, may reduce contraceptive effectiveness and pose risks to pregnant women and fetuses, prompting advice on birth control and immediate cessation upon pregnancy.
Progress
60% Bias Score
Weight-Loss Drugs Linked to Increased Osteoporosis Risk
Weight-loss drugs such as Ozempic, Wegovy, and Mounjaro may cause significant bone and muscle loss, increasing osteoporosis risk, according to the Royal Osteoporosis Society. Up to 40 percent of weight loss from these drugs may come from bone and muscle, impacting approximately half a million users ...
Weight-Loss Drugs Linked to Increased Osteoporosis Risk
Weight-loss drugs such as Ozempic, Wegovy, and Mounjaro may cause significant bone and muscle loss, increasing osteoporosis risk, according to the Royal Osteoporosis Society. Up to 40 percent of weight loss from these drugs may come from bone and muscle, impacting approximately half a million users ...
Progress
56% Bias Score
GLP-1 Agonists Show Potential for Reducing Obesity-Related Cancer Risk
A new study of 170,030 obese and diabetic adults in the US found that GLP-1 receptor agonists (Ozempic, Wegovy, etc.) may modestly reduce the risk of 14 obesity-related cancers and all-cause mortality, especially in women, compared to DDP-4 inhibitors.
GLP-1 Agonists Show Potential for Reducing Obesity-Related Cancer Risk
A new study of 170,030 obese and diabetic adults in the US found that GLP-1 receptor agonists (Ozempic, Wegovy, etc.) may modestly reduce the risk of 14 obesity-related cancers and all-cause mortality, especially in women, compared to DDP-4 inhibitors.
Progress
44% Bias Score
GLP-1 Weight-Loss Drugs May Reduce Obesity-Related Cancer Risk by 41%
A study of nearly 6,400 obese and diabetic individuals found that GLP-1 receptor agonists, while less effective for weight loss than bariatric surgery, may reduce obesity-related cancer risk by 41%, potentially through inflammation reduction; however, this observational study requires further invest...
GLP-1 Weight-Loss Drugs May Reduce Obesity-Related Cancer Risk by 41%
A study of nearly 6,400 obese and diabetic individuals found that GLP-1 receptor agonists, while less effective for weight loss than bariatric surgery, may reduce obesity-related cancer risk by 41%, potentially through inflammation reduction; however, this observational study requires further invest...
Progress
20% Bias Score
Showing 1 to 12 of 22 results